Search RXRX
Recursion Pharmaceuticals, Inc.
NasdaqGS · CIK 1601830
Last close4.12
Daily change+0.05 (1.23%)
10 Years gain-86.84%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
RXRX · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
39.5Momentum
0.0Acceleration
0.0Confidence
75.0Annual Revenue7
Quarterly Revenue24
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth12.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 74.0308 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 882.8698 percentage points.
Heavy share dilution · HIGHDiluted share count increased 32.1989%.
Key Metrics
Revenue Growth TTM-44.18%OK
Revenue CAGR 3Y23.3%OK
Gross Margin-52.64%OK
Operating Margin-1,587.71%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-120.43%OK
Incremental Operating Margin 3Y-6,961.06%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y32.2%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $74.68M | $3.73M | -$648.13M | -$371.81M | -$378.28M | 4.99% | -867.87% | -506.52% | -123.68% | 447.45M |
| 2025 FY Dec 31, 2024 | $58.84M | $13.60M | -$479.00M | -$359.17M | -$372.87M | 23.12% | -814.09% | -633.71% | -147.73% | 274.21M |
| 2025 FY Dec 31, 2023 | $44.58M | $1.99M | -$350.06M | -$287.78M | -$299.74M | 4.46% | -785.33% | -672.43% | -7,122.92% | 207.85M |
| 2024 FY Dec 31, 2022 | $39.84M | -$8.43M | -$245.73M | -$83.52M | -$120.58M | -21.16% | -616.74% | -302.65% | n/a | 175.54M |
| 2023 FY Dec 31, 2021 | $10.18M | $10.18M | -$182.78M | -$158.61M | -$198.41M | 100% | -1,795.79% | -1,949.42% | n/a | 125.35M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $38.54M | sum latest 4 fiscal quarters Revenue | OK | 0001601830-26-000098, 0001601830-25-000166 |
| Revenue Growth TTM | -44.18% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001601830-26-000098, 0001601830-25-000166 |
| Revenue CAGR 3Y | 23.3% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001601830-26-000039 |
| Revenue CAGR 5Y | 79.91% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001601830-26-000039 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001601830-26-000039 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001601830-26-000098, 0001601830-25-000166 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | -52.64% | Gross Profit / Revenue | OK | 0001601830-26-000098, 0001601830-25-000166 |
| Operating Margin | -1,587.71% | Operating Income / Revenue | OK | 0001601830-26-000098, 0001601830-25-000166 |
| ROIC | -120.43% | NOPAT / Average Invested Capital | OK | 0001601830-26-000098, 0001601830-25-000166 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001601830-26-000098 |
| Current Ratio | 5.03x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.07 | Revenue / Diluted Shares | OK | 0001601830-26-000098, 0001601830-25-000166 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |